In this episode, Prof Benoit Tessoulin examines how real-world evidence from the French DESCAR-T registry is expanding our understanding of CAR T-cell therapy beyond clinical trials. He explains how the registry captures data from patients considered for CAR T-cell treatment, including those who do not ultimately receive therapy, and explores what these data reveal about patient selection, treatment outcomes, bridging therapy, and comparisons between different CAR T-cell products.
The discussion also examines how real-world populations differ from clinical trial cohorts, in what measure registry data have confirmed the effectiveness of CAR T-cell therapy in routine practice, and what has been learned about toxicities such as CRS, ICANS, and infections. Prof Tessoulin highlights the importance of timely referral, evolving product selection strategies, and the growing role of patient registries in informing clinical decision-making and future research. Listen now for insights into how real-world data are informing CAR T-cell therapy updates.
This podcast episode is supported by Bristol Myers Squibb.
Guest: Prof Benoit Tessoulin
Affiliation: Hematology Department, Centre Hospitalier Universitaire Nantes, France
Host: Isabel Olivera-Martínez, PhD, Medical Writer for EHA
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
